title: Which patients with resectable pancreatic cancer truly benefit from oncological resection: is it destiny or biology?
abstract: Pancreatic cancer has a dismal prognosis. A technically perfect surgical operation may still not provide a survival advantage for patients with technically resectable pancreatic cancer. Appropriate selection of patients for surgical resections is an imminent issue. Recent studies have provided an important clue on what serum biomarkers may be used to select out the patients who would unlikely benefit from the surgical resection.
authors.affiliation: a Departments of Oncology and Surgery ; Johns Hopkins University School of Medicine ; Baltimore , MD USA.
authors.forename: Lei
authors.initials: L
authors.lastname: Zheng
authors.forename: Christopher L
authors.initials: CL
authors.lastname: Wolfgang
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor
keywords: pancreatic cancer; serum biomarker; surgery